Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Annovis Bio, Inc.
NYSE:ANVSHealthcare · Biotechnology
+10.78%$1.13
AH$1.12-0.57%vs close
Mkt Cap$48.23M
Float37.15M
O/S42.68M
Vol
$ Vol
RVOL
Inst Own25.3%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$28.85M
Total Assets$21.08M
Free Cash Flow-$25.62M
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$16.85M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in ANVS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$21.08M
Liabilities$4.23M
Accounts Receivable$0
Accounts Payable$2.59M
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - | - | - |
| Research and Development | $25.22M | $20M | $38.79M | $16.52M | $8.48M | $3.05M | $776K | $112K | $273K |
| Selling, General, and Administrative | $4.48M | $6.7M | $6.24M | $9M | $6.06M | $3.59M | $829K | $602K | $409K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $378 | $0 | $0 |
| Total Operating Expenses | $29.7M | $26.69M | $45.03M | $25.51M | $14.54M | $6.64M | $1.61M | $714K | $682K |
| Operating Income (EBIT) | -$29.7M | -$26.69M | -$45.03M | -$25.51M | -$14.54M | -$6.64M | -$1.61M | -$714K | -$682K |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Interest Expense | $0 | $1.85M | $0 | $0 | $0 | $47.23M | $0 | $66 | $84 |
| Interest Income | $699K | $332K | $668K | $183K | $13K | $47K | $0 | $0 | $0 |
| Other Income (Expense) | $841K | $2.1M | -$11.17M | $183K | $50K | $1.18M | $615K | $66 | $84 |
| Income Before Tax (EBT) | -$28.85M | -$24.59M | -$56.2M | -$25.33M | -$14.49M | -$5.46M | -$991K | -$714K | -$682K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$132 | $0 |
| Net Income | -$28.85M | -$24.59M | -$56.2M | -$25.33M | -$14.49M | -$5.46M | -$991K | -$714K | -$682K |
| Net Income Margin | - | - | - | - | - | - | - | - | - |
| Supplementary Data | |||||||||
| EPS | -1.40 | -2.02 | -6.23 | -3.10 | -1.90 | -0.87 | -0.14 | -0.10 | -0.10 |
| Diluted EPS | -1.40 | -2.31 | -6.23 | -3.10 | -1.90 | -0.87 | -0.14 | -0.10 | -0.10 |
| Weighted Average OS | 20.55M | 12.18M | 9.02M | 8.16M | 7.63M | 6.31M | 6.85M | 6.82M | 6.82M |
| EBITDA | -$28.85M | -$22.74M | -$56.2M | -$25.33M | -$14.5M | $0 | -$378 | -$63 | $433 |
| EBITDA Margin | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $19.53M | $10.55M | $5.75M | $28.38M | $45.69M | $8.07M | $2K | $35K | $347K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $19.53M | $10.55M | $5.75M | $28.38M | $45.69M | $8.07M | $2K | $35K | $347K |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $735K | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | -$745.64M | $0 | $0 |
| Other Current Assets | $7K | $7K | $21K | $7.54M | $10K | $6K | $746K | $0 | $0 |
| Total Current Assets | $21.08M | $13.93M | $10.21M | $36.02M | $46M | $8.12M | $748K | $51K | $358K |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $0 | $0 | $0 | $370K | $0 | $0 |
| Total Long-Term Assets | $0 | $0 | $0 | $0 | $0 | $0 | $370K | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $21.08M | $13.93M | $10.21M | $36.02M | $46M | $8.12M | $1.12M | $51K | $358K |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $2.59M | $2.31M | $1.29M | $3.96M | $688K | $342K | $1.23M | $68K | $71K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $619K | $1.21M | $273 | $0 | $106K | $220K | $645K | $478K | $415K |
| Total Current Liabilities | $3.64M | $3.88M | $4.28M | $7.7M | $1.51M | $578K | $2.01M | $568K | $490K |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $500K | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $595K | $737K | $13.68M | $0 | $0 | $0 | $7.18M | $7K | $6.83M |
| Total Long-Term Liabilities | $595K | $737K | $13.68M | $0 | $0 | $0 | $7.68M | $7K | $6.83M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.23M | $4.62M | $17.96M | $7.7M | $1.51M | $578K | $9.69M | $7.64M | $7.32M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $7.08M | $7.08M | $6.83M |
| Common Stock | $3K | $1K | $1K | $816 | $810 | $689 | $0 | $0 | $0 |
| Retained Earnings | -$163.7M | -$134.85M | -$110.26M | -$54.05M | -$28.73M | -$14.24M | -$8.78M | -$7.79M | -$7.07M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 | -$7.08M | -$7.08M | -$6.83M |
| Other Stockholders' Equity | $180.55M | $144.16M | $102.51M | $82.38M | $73.22M | $21.78M | $201K | $192K | $107K |
| Total Equity | $16.85M | $9.31M | -$7.75M | $28.32M | $44.49M | $7.54M | -$8.58M | -$7.59M | -$6.97M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $21.08M | $13.93M | $10.21M | $36.02M | $46M | $8.12M | $1.12M | $51K | $358K |
| Supplementary Data | |||||||||
| Total Debt | $0 | $0 | $0 | $0 | $0 | $0 | $500K | $0 | $0 |
| Net Debt | -$19.53M | -$10.55M | -$5.75M | -$28.38M | -$45.69M | -$8.07M | $498K | -$35K | -$347K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$28.85M | -$24.59M | -$56.2M | -$25.33M | -$14.49M | -$5.46M | -$991K | -$714K | -$682K |
| Depreciation & Amortization | $0 | $0 | $0 | $0 | $0 | $6.64M | $1.61M | $714K | $682K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | -$1.19M | $0 | $0 |
| Stock-Based Compensation | $1.8M | $3.84M | $4.63M | $9.15M | $4.7M | $1.86M | $8K | $83K | $48K |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $735K | -$735K | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $735K | $0 | $0 |
| Accounts Payable | $285K | $1.01M | -$2.67M | $3.27M | $346K | -$696K | $969K | -$3K | $62K |
| Other Working Capital | $1.29M | -$331K | $2.44M | -$4.41M | $311K | -$440K | -$548K | $75K | $35K |
| Total Working Capital Change | $1.58M | $682K | -$229K | -$1.14M | $657K | -$401K | $422K | $73K | $96K |
| Other Non-Cash Items | -$142K | -$1.82M | $11.84M | $0 | $0 | -$6.61M | -$330K | -$714K | -$682K |
| Net Cash from Operating | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -$9.13M | -$3.97M | -$477K | -$559K | -$537K |
| Investing Activities | |||||||||
| Capital Expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Activities | |||||||||
| Debt Repaid | - | - | - | - | - | -$12.03M | -$530K | - | - |
| Common Stock Issuance | $34.6M | $26.69M | $16.89M | $5K | $46.65M | $9K | -$79K | $3K | $8K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $458K | $0 | $95K | $0 | -$87K | $246K | $332K |
| Net Cash from Financing | $34.6M | $26.69M | $17.34M | $5K | $46.74M | $12.04M | $443K | $246K | $332K |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | -$1 | $0 | $0 | $0 |
| Net Change in Cash | $8.98M | $4.8M | -$22.62M | -$17.31M | $37.61M | $8.07M | -$33K | -$312K | -$205K |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -$9.13M | -$3.97M | -$477K | -$559K | -$537K |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | $3 | $0 | $0 | $0 |
| Free Cash Flow | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -$9.13M | -$3.97M | -$477K | -$559K | -$537K |
| Cash at Beginning | $10.55M | $5.75M | $28.38M | $45.69M | $8.07M | $2K | $35K | $347K | $552K |
| Cash at End | $19.53M | $10.55M | $5.75M | $28.38M | $45.69M | $8.07M | $2K | $35K | $347K |